Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 8, 2023, the Company appointed Dr.. | May 11, 2023
Company successfully submits GTX-104 Pivotal Phase 3 protocol IND amendment to the FDA with expectation for first patient dosed in calendar Q4 2023
Strategic realignment prioritizes GTX-104 and. | May 8, 2023
LAVAL, Québec, Sept. 30, 2022 Acasti Pharma Inc. , a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases,. | September 30, 2022
Phoenix, Arizona (Newsfile Corp. - February 22, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and